Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Begelomab add-on therapy in dermatomyositis
2021-000898-83Phase 2Terminated
- Sponsor
- Adienne
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of begelomab in dermatomyositis (DM) (2 arms), sponsored by Adienne. Primary endpoint: IMACS total improvement score at Day 31. Started Oct 2021; status: terminated.
02
Drugs
begelomab
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on 2021-000898-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000898-83.